Conformationally restricted analogues of nicotine and anabasine
A series of conformationally restricted analogues of nicotine has been synthesized and evaluated as agonists of neuronal acetylcholine receptors. Compounds 2 (SIB-1663), which selectively activated human recombinant α2β4 and α4β4 nAChRs, was shown to be active in animal models of Parkinson's di...
Gespeichert in:
| Veröffentlicht in: | Bioorganic & medicinal chemistry letters 1998-08, Vol.8 (16), p.2173-2178 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2178 |
|---|---|
| container_issue | 16 |
| container_start_page | 2173 |
| container_title | Bioorganic & medicinal chemistry letters |
| container_volume | 8 |
| creator | Vernier, Jean-Michel Holsenback, Heather Cosford, Nicholas D.P. Whitten, Jeffrey P. Menzaghi, Frédérique Reid, Richard Rao, Tadimeti S. Sacaan, Aida I. Lloyd, G.Kenneth Suto, Carla M. Chavez-Noriega, Laura E. Washburn, Mark S. Urrutia, Arturo McDonald, Ian A. |
| description | A series of conformationally restricted analogues of nicotine has been synthesized and evaluated as agonists of neuronal acetylcholine receptors. Compounds
2 (SIB-1663), which selectively activated human recombinant α2β4 and α4β4 nAChRs, was shown to be active in animal models of Parkinson's disease and pain.
A series of conformationally restricted analogues of nicotine has been synthesized and evaluated as agonists of neuronal acetylcholine receptors. Compound
2 (SIB-1663), which selectively activated human recombinant α2β4 and α4β4 nAChRs, was shown to be active in animal models of Parkinson's disease and pain. |
| doi_str_mv | 10.1016/S0960-894X(98)00394-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69114263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960894X98003941</els_id><sourcerecordid>69114263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-45dad86432b56edbf78471fa8cbce611a41edf7910c3f6b62329057919b977113</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMotVZ_QqEHET2sZjbZbHIqUvyCggcVvIVsdiKR7aYmW6H_3u0HvXoaZt535h0eQsZAb4GCuHujStBMKv55reQNpUzxDI7IELjgGeO0OCbDg-WUnKX0TSlwyvmADJQsWUHlkExnoXUhLkznQ2uaZj2JmLrobYf1xPST8LXCNAlu0nobOt9iP90qlUl9d05OnGkSXuzriHw8PrzPnrP569PL7H6eWSZVl_GiNrUUnOVVIbCuXCl5Cc5IW1kUAIYD1q5UQC1zohI5yxUt-l5VqiwB2Ihc7e4uY_jpP-r0wieLTWNaDKukhQLguWC9sdgZbQwpRXR6Gf3CxLUGqjfg9Bac3lDRSuotOL0JGO8DVtUC68PWnlSvX-51k6xpXDSt9elgy5lQCjbx050Nexi_HqNO1mNrsfYRbafr4P955A9HUYpQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69114263</pqid></control><display><type>article</type><title>Conformationally restricted analogues of nicotine and anabasine</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Vernier, Jean-Michel ; Holsenback, Heather ; Cosford, Nicholas D.P. ; Whitten, Jeffrey P. ; Menzaghi, Frédérique ; Reid, Richard ; Rao, Tadimeti S. ; Sacaan, Aida I. ; Lloyd, G.Kenneth ; Suto, Carla M. ; Chavez-Noriega, Laura E. ; Washburn, Mark S. ; Urrutia, Arturo ; McDonald, Ian A.</creator><creatorcontrib>Vernier, Jean-Michel ; Holsenback, Heather ; Cosford, Nicholas D.P. ; Whitten, Jeffrey P. ; Menzaghi, Frédérique ; Reid, Richard ; Rao, Tadimeti S. ; Sacaan, Aida I. ; Lloyd, G.Kenneth ; Suto, Carla M. ; Chavez-Noriega, Laura E. ; Washburn, Mark S. ; Urrutia, Arturo ; McDonald, Ian A.</creatorcontrib><description>A series of conformationally restricted analogues of nicotine has been synthesized and evaluated as agonists of neuronal acetylcholine receptors. Compounds
2 (SIB-1663), which selectively activated human recombinant α2β4 and α4β4 nAChRs, was shown to be active in animal models of Parkinson's disease and pain.
A series of conformationally restricted analogues of nicotine has been synthesized and evaluated as agonists of neuronal acetylcholine receptors. Compound
2 (SIB-1663), which selectively activated human recombinant α2β4 and α4β4 nAChRs, was shown to be active in animal models of Parkinson's disease and pain.</description><identifier>ISSN: 0960-894X</identifier><identifier>EISSN: 1464-3405</identifier><identifier>DOI: 10.1016/S0960-894X(98)00394-1</identifier><identifier>PMID: 9873508</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Anabasine - analogs & derivatives ; Anabasine - chemical synthesis ; Anabasine - chemistry ; Anabasine - pharmacology ; Animals ; Antiparkinson Agents - chemical synthesis ; Antiparkinson Agents - chemistry ; Antiparkinson Agents - pharmacology ; Biological and medical sciences ; Calcium - metabolism ; Cell Line ; Cholinergic Agonists - chemical synthesis ; Cholinergic Agonists - chemistry ; Cholinergic Agonists - pharmacology ; Cholinergic system ; Drug Design ; Humans ; Macromolecular Substances ; Medical sciences ; Molecular Conformation ; Neurons - metabolism ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Nicotine - analogs & derivatives ; Nicotine - chemical synthesis ; Nicotine - chemistry ; Nicotine - pharmacology ; Parkinson Disease, Secondary - drug therapy ; Pharmacology. Drug treatments ; Piperidines - chemical synthesis ; Piperidines - chemistry ; Piperidines - pharmacology ; Pyridines - chemical synthesis ; Pyridines - chemistry ; Pyridines - pharmacology ; Recombinant Proteins - drug effects ; Structure-Activity Relationship ; Transfection</subject><ispartof>Bioorganic & medicinal chemistry letters, 1998-08, Vol.8 (16), p.2173-2178</ispartof><rights>1998</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-45dad86432b56edbf78471fa8cbce611a41edf7910c3f6b62329057919b977113</citedby><cites>FETCH-LOGICAL-c389t-45dad86432b56edbf78471fa8cbce611a41edf7910c3f6b62329057919b977113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0960-894X(98)00394-1$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2369913$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9873508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vernier, Jean-Michel</creatorcontrib><creatorcontrib>Holsenback, Heather</creatorcontrib><creatorcontrib>Cosford, Nicholas D.P.</creatorcontrib><creatorcontrib>Whitten, Jeffrey P.</creatorcontrib><creatorcontrib>Menzaghi, Frédérique</creatorcontrib><creatorcontrib>Reid, Richard</creatorcontrib><creatorcontrib>Rao, Tadimeti S.</creatorcontrib><creatorcontrib>Sacaan, Aida I.</creatorcontrib><creatorcontrib>Lloyd, G.Kenneth</creatorcontrib><creatorcontrib>Suto, Carla M.</creatorcontrib><creatorcontrib>Chavez-Noriega, Laura E.</creatorcontrib><creatorcontrib>Washburn, Mark S.</creatorcontrib><creatorcontrib>Urrutia, Arturo</creatorcontrib><creatorcontrib>McDonald, Ian A.</creatorcontrib><title>Conformationally restricted analogues of nicotine and anabasine</title><title>Bioorganic & medicinal chemistry letters</title><addtitle>Bioorg Med Chem Lett</addtitle><description>A series of conformationally restricted analogues of nicotine has been synthesized and evaluated as agonists of neuronal acetylcholine receptors. Compounds
2 (SIB-1663), which selectively activated human recombinant α2β4 and α4β4 nAChRs, was shown to be active in animal models of Parkinson's disease and pain.
A series of conformationally restricted analogues of nicotine has been synthesized and evaluated as agonists of neuronal acetylcholine receptors. Compound
2 (SIB-1663), which selectively activated human recombinant α2β4 and α4β4 nAChRs, was shown to be active in animal models of Parkinson's disease and pain.</description><subject>Anabasine - analogs & derivatives</subject><subject>Anabasine - chemical synthesis</subject><subject>Anabasine - chemistry</subject><subject>Anabasine - pharmacology</subject><subject>Animals</subject><subject>Antiparkinson Agents - chemical synthesis</subject><subject>Antiparkinson Agents - chemistry</subject><subject>Antiparkinson Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Calcium - metabolism</subject><subject>Cell Line</subject><subject>Cholinergic Agonists - chemical synthesis</subject><subject>Cholinergic Agonists - chemistry</subject><subject>Cholinergic Agonists - pharmacology</subject><subject>Cholinergic system</subject><subject>Drug Design</subject><subject>Humans</subject><subject>Macromolecular Substances</subject><subject>Medical sciences</subject><subject>Molecular Conformation</subject><subject>Neurons - metabolism</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Nicotine - analogs & derivatives</subject><subject>Nicotine - chemical synthesis</subject><subject>Nicotine - chemistry</subject><subject>Nicotine - pharmacology</subject><subject>Parkinson Disease, Secondary - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - chemical synthesis</subject><subject>Piperidines - chemistry</subject><subject>Piperidines - pharmacology</subject><subject>Pyridines - chemical synthesis</subject><subject>Pyridines - chemistry</subject><subject>Pyridines - pharmacology</subject><subject>Recombinant Proteins - drug effects</subject><subject>Structure-Activity Relationship</subject><subject>Transfection</subject><issn>0960-894X</issn><issn>1464-3405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhoMotVZ_QqEHET2sZjbZbHIqUvyCggcVvIVsdiKR7aYmW6H_3u0HvXoaZt535h0eQsZAb4GCuHujStBMKv55reQNpUzxDI7IELjgGeO0OCbDg-WUnKX0TSlwyvmADJQsWUHlkExnoXUhLkznQ2uaZj2JmLrobYf1xPST8LXCNAlu0nobOt9iP90qlUl9d05OnGkSXuzriHw8PrzPnrP569PL7H6eWSZVl_GiNrUUnOVVIbCuXCl5Cc5IW1kUAIYD1q5UQC1zohI5yxUt-l5VqiwB2Ihc7e4uY_jpP-r0wieLTWNaDKukhQLguWC9sdgZbQwpRXR6Gf3CxLUGqjfg9Bac3lDRSuotOL0JGO8DVtUC68PWnlSvX-51k6xpXDSt9elgy5lQCjbx050Nexi_HqNO1mNrsfYRbafr4P955A9HUYpQ</recordid><startdate>19980818</startdate><enddate>19980818</enddate><creator>Vernier, Jean-Michel</creator><creator>Holsenback, Heather</creator><creator>Cosford, Nicholas D.P.</creator><creator>Whitten, Jeffrey P.</creator><creator>Menzaghi, Frédérique</creator><creator>Reid, Richard</creator><creator>Rao, Tadimeti S.</creator><creator>Sacaan, Aida I.</creator><creator>Lloyd, G.Kenneth</creator><creator>Suto, Carla M.</creator><creator>Chavez-Noriega, Laura E.</creator><creator>Washburn, Mark S.</creator><creator>Urrutia, Arturo</creator><creator>McDonald, Ian A.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980818</creationdate><title>Conformationally restricted analogues of nicotine and anabasine</title><author>Vernier, Jean-Michel ; Holsenback, Heather ; Cosford, Nicholas D.P. ; Whitten, Jeffrey P. ; Menzaghi, Frédérique ; Reid, Richard ; Rao, Tadimeti S. ; Sacaan, Aida I. ; Lloyd, G.Kenneth ; Suto, Carla M. ; Chavez-Noriega, Laura E. ; Washburn, Mark S. ; Urrutia, Arturo ; McDonald, Ian A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-45dad86432b56edbf78471fa8cbce611a41edf7910c3f6b62329057919b977113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Anabasine - analogs & derivatives</topic><topic>Anabasine - chemical synthesis</topic><topic>Anabasine - chemistry</topic><topic>Anabasine - pharmacology</topic><topic>Animals</topic><topic>Antiparkinson Agents - chemical synthesis</topic><topic>Antiparkinson Agents - chemistry</topic><topic>Antiparkinson Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Calcium - metabolism</topic><topic>Cell Line</topic><topic>Cholinergic Agonists - chemical synthesis</topic><topic>Cholinergic Agonists - chemistry</topic><topic>Cholinergic Agonists - pharmacology</topic><topic>Cholinergic system</topic><topic>Drug Design</topic><topic>Humans</topic><topic>Macromolecular Substances</topic><topic>Medical sciences</topic><topic>Molecular Conformation</topic><topic>Neurons - metabolism</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Nicotine - analogs & derivatives</topic><topic>Nicotine - chemical synthesis</topic><topic>Nicotine - chemistry</topic><topic>Nicotine - pharmacology</topic><topic>Parkinson Disease, Secondary - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - chemical synthesis</topic><topic>Piperidines - chemistry</topic><topic>Piperidines - pharmacology</topic><topic>Pyridines - chemical synthesis</topic><topic>Pyridines - chemistry</topic><topic>Pyridines - pharmacology</topic><topic>Recombinant Proteins - drug effects</topic><topic>Structure-Activity Relationship</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vernier, Jean-Michel</creatorcontrib><creatorcontrib>Holsenback, Heather</creatorcontrib><creatorcontrib>Cosford, Nicholas D.P.</creatorcontrib><creatorcontrib>Whitten, Jeffrey P.</creatorcontrib><creatorcontrib>Menzaghi, Frédérique</creatorcontrib><creatorcontrib>Reid, Richard</creatorcontrib><creatorcontrib>Rao, Tadimeti S.</creatorcontrib><creatorcontrib>Sacaan, Aida I.</creatorcontrib><creatorcontrib>Lloyd, G.Kenneth</creatorcontrib><creatorcontrib>Suto, Carla M.</creatorcontrib><creatorcontrib>Chavez-Noriega, Laura E.</creatorcontrib><creatorcontrib>Washburn, Mark S.</creatorcontrib><creatorcontrib>Urrutia, Arturo</creatorcontrib><creatorcontrib>McDonald, Ian A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic & medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vernier, Jean-Michel</au><au>Holsenback, Heather</au><au>Cosford, Nicholas D.P.</au><au>Whitten, Jeffrey P.</au><au>Menzaghi, Frédérique</au><au>Reid, Richard</au><au>Rao, Tadimeti S.</au><au>Sacaan, Aida I.</au><au>Lloyd, G.Kenneth</au><au>Suto, Carla M.</au><au>Chavez-Noriega, Laura E.</au><au>Washburn, Mark S.</au><au>Urrutia, Arturo</au><au>McDonald, Ian A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conformationally restricted analogues of nicotine and anabasine</atitle><jtitle>Bioorganic & medicinal chemistry letters</jtitle><addtitle>Bioorg Med Chem Lett</addtitle><date>1998-08-18</date><risdate>1998</risdate><volume>8</volume><issue>16</issue><spage>2173</spage><epage>2178</epage><pages>2173-2178</pages><issn>0960-894X</issn><eissn>1464-3405</eissn><abstract>A series of conformationally restricted analogues of nicotine has been synthesized and evaluated as agonists of neuronal acetylcholine receptors. Compounds
2 (SIB-1663), which selectively activated human recombinant α2β4 and α4β4 nAChRs, was shown to be active in animal models of Parkinson's disease and pain.
A series of conformationally restricted analogues of nicotine has been synthesized and evaluated as agonists of neuronal acetylcholine receptors. Compound
2 (SIB-1663), which selectively activated human recombinant α2β4 and α4β4 nAChRs, was shown to be active in animal models of Parkinson's disease and pain.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>9873508</pmid><doi>10.1016/S0960-894X(98)00394-1</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-894X |
| ispartof | Bioorganic & medicinal chemistry letters, 1998-08, Vol.8 (16), p.2173-2178 |
| issn | 0960-894X 1464-3405 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69114263 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Anabasine - analogs & derivatives Anabasine - chemical synthesis Anabasine - chemistry Anabasine - pharmacology Animals Antiparkinson Agents - chemical synthesis Antiparkinson Agents - chemistry Antiparkinson Agents - pharmacology Biological and medical sciences Calcium - metabolism Cell Line Cholinergic Agonists - chemical synthesis Cholinergic Agonists - chemistry Cholinergic Agonists - pharmacology Cholinergic system Drug Design Humans Macromolecular Substances Medical sciences Molecular Conformation Neurons - metabolism Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Nicotine - analogs & derivatives Nicotine - chemical synthesis Nicotine - chemistry Nicotine - pharmacology Parkinson Disease, Secondary - drug therapy Pharmacology. Drug treatments Piperidines - chemical synthesis Piperidines - chemistry Piperidines - pharmacology Pyridines - chemical synthesis Pyridines - chemistry Pyridines - pharmacology Recombinant Proteins - drug effects Structure-Activity Relationship Transfection |
| title | Conformationally restricted analogues of nicotine and anabasine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T09%3A03%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conformationally%20restricted%20analogues%20of%20nicotine%20and%20anabasine&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry%20letters&rft.au=Vernier,%20Jean-Michel&rft.date=1998-08-18&rft.volume=8&rft.issue=16&rft.spage=2173&rft.epage=2178&rft.pages=2173-2178&rft.issn=0960-894X&rft.eissn=1464-3405&rft_id=info:doi/10.1016/S0960-894X(98)00394-1&rft_dat=%3Cproquest_cross%3E69114263%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69114263&rft_id=info:pmid/9873508&rft_els_id=S0960894X98003941&rfr_iscdi=true |